Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment

Lucia Nogova, Christian Mattonet, Matthias Scheffler, Max Taubert, Masyar Gardizi, Martin L. Sos, Sebastian Michels, Rieke N. Fischer, Meike Limburg, Diana S.Y. Abdulla, Thorsten Persigehl, Carsten Kobe, Sabine Merkelbach‐Bruse, Jeremy Franklin, Heiko Backes, Roland Schnell, Dirk Behringer, Britta Kaminsky, Martina Eichstaedt, Christoph Stelzer, Martina Kinzig, Fritz Sörgel, Yingying Tian, Lisa Junge, Ahmed A. Suleiman, Sebastian Frechen, Dennis Rokitta, Dongsheng Ouyang, Uwe Fuhr, Reinhard Buettner, Jürgen Wolf

Open source

DOI: 10.1002/cam4.3131
Published: 2020-05-21
Container: Cancer Medicine
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/cam4.3131,
  title = {Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment},
  author = {Lucia Nogova and Christian Mattonet and Matthias Scheffler and Max Taubert and Masyar Gardizi and Martin L. Sos and Sebastian Michels and Rieke N. Fischer and Meike Limburg and Diana S.Y. Abdulla and Thorsten Persigehl and Carsten Kobe and Sabine Merkelbach‐Bruse and Jeremy Franklin and Heiko Backes and Roland Schnell and Dirk Behringer and Britta Kaminsky and Martina Eichstaedt and Christoph Stelzer and Martina Kinzig and Fritz Sörgel and Yingying Tian and Lisa Junge and Ahmed A. Suleiman and Sebastian Frechen and Dennis Rokitta and Dongsheng Ouyang and Uwe Fuhr and Reinhard Buettner and Jürgen Wolf},
  year = {2020},
  journal = {Cancer Medicine},
  doi = {10.1002/cam4.3131},
  url = {https://doi.org/10.1002/cam4.3131}
}

RIS

TY  - JOUR
TI  - Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment
AU  - Lucia Nogova
AU  - Christian Mattonet
AU  - Matthias Scheffler
AU  - Max Taubert
AU  - Masyar Gardizi
AU  - Martin L. Sos
AU  - Sebastian Michels
AU  - Rieke N. Fischer
AU  - Meike Limburg
AU  - Diana S.Y. Abdulla
AU  - Thorsten Persigehl
AU  - Carsten Kobe
AU  - Sabine Merkelbach‐Bruse
AU  - Jeremy Franklin
AU  - Heiko Backes
AU  - Roland Schnell
AU  - Dirk Behringer
AU  - Britta Kaminsky
AU  - Martina Eichstaedt
AU  - Christoph Stelzer
AU  - Martina Kinzig
AU  - Fritz Sörgel
AU  - Yingying Tian
AU  - Lisa Junge
AU  - Ahmed A. Suleiman
AU  - Sebastian Frechen
AU  - Dennis Rokitta
AU  - Dongsheng Ouyang
AU  - Uwe Fuhr
AU  - Reinhard Buettner
AU  - Jürgen Wolf
PY  - 2020
JO  - Cancer Medicine
DO  - 10.1002/cam4.3131
UR  - https://doi.org/10.1002/cam4.3131
ER  -

APA

Nogova, L., Mattonet, C., Scheffler, M., Taubert, M., Gardizi, M., Sos, M. L., Michels, S., Fischer, R. N., Limburg, M., Abdulla, D. S., Persigehl, T., Kobe, C., Merkelbach‐Bruse, S., Franklin, J., Backes, H., Schnell, R., Behringer, D., Kaminsky, B., Eichstaedt, M., Stelzer, C., Kinzig, M., Sörgel, F., Tian, Y., Junge, L., Suleiman, A. A., Frechen, S., Rokitta, D., Ouyang, D., Fuhr, U., Buettner, R., & Wolf, J. (2020). Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment. Cancer Medicine. https://doi.org/10.1002/cam4.3131

Source records

crossref · retrieved 2026-09-26T03:13:41.457Z